News
12 May 2026
Frost & Sullivan’s 2026 Global Company of the Year
Frost & Sullivan is pleased to announce that Avance Clinical has been awarded the 2026 Global Company of the Year Recognition in the biotechnology contract research organization (CRO) industry for its outstanding achievements in innovation, strategy execution, and customer impact.
4 June 2024
New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Deliver 30% Savings, Halve Timelines and Cut Risk for Biotechs
Avance Clinical is sharing new data at BIO 2024 from Frost & Sullivan research showing biotechs save more than 30% in costs and halve start-up times with CROs that have in-house scientific and regulatory affairs.
8 January 2024
Frost & Sullivan Analysis Reveals 65% of US Biotechs Struggle to Identify Suitable CRO Partner
Avance Clinical, the leading Australian and North American CRO for biotechs announced today that new industry analysis shows 60-65% of US biotechs face challenges identifying the right sized CRO partner that can deliver at every phase of their drug development program. The report found this directly affected clinical programs and budgets.
Proven industry
experience & expertise
800+
Studies in the past 10 years
500+
Experienced team members
33k+
Participants past 10 years
30
Years of CRO experience